The Role of Surface Active Agents in Ophthalmic Drug Delivery: A Comprehensive Review
- PMID: 30684539
- DOI: 10.1016/j.xphs.2019.01.016
The Role of Surface Active Agents in Ophthalmic Drug Delivery: A Comprehensive Review
Abstract
With the significant advances made in nanotechnology, research efforts focused on developing novel drug delivery platforms that can overcome the multitude of challenges encountered in ophthalmic drug delivery. Surface active agents (SAAs) have been extensively used for the formulation of many of the dosage forms targeting ocular tissues. Novel ophthalmic carriers utilizing SAAs were broadly classified into particulate, vesicular, and controlled release drug delivery systems. Depending on their physicochemical properties, SAAs can perform a variety of roles ranging from wetting agents, emulsifiers, stabilizers, charge inducers, solubilizers, antimicrobial agents, corneal permeation enhancers, and gelling agents. Nevertheless, their use is limited by their potential toxicity and possible interactions with other formulation ingredients. This review provides a comprehensive analysis of the different functional roles of SAAs in novel ophthalmic drug delivery platforms, their mechanism of action, and limitations that need to be considered during formulation to maximize their potential benefit. Understanding the mechanisms by which they perform their different roles and the possible interactions between SAAs and other formulation ingredients can help orientate the choice of formulators toward the SAA most suitable for the intended ocular application at a concentration that is both safe and effective.
Keywords: drug-excipient interactions; formulation; ophthalmic; permeation enhancer; physicochemical properties; poorly water soluble drugs; solubilization; surface active; surfactants.
Copyright © 2019 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies.Eur J Pharm Biopharm. 2012 Jun;81(2):257-64. doi: 10.1016/j.ejpb.2012.02.014. Epub 2012 Mar 16. Eur J Pharm Biopharm. 2012. PMID: 22445900
-
Novel Ocular Drug Delivery Systems: An Update on Microemulsions.J Ocul Pharmacol Ther. 2020 Jul/Aug;36(6):342-354. doi: 10.1089/jop.2019.0135. Epub 2020 Apr 7. J Ocul Pharmacol Ther. 2020. PMID: 32255728 Review.
-
Ocular preparations: the formulation approach.Drug Dev Ind Pharm. 2002 May;28(5):473-93. doi: 10.1081/ddc-120003445. Drug Dev Ind Pharm. 2002. PMID: 12098838 Review.
-
Optimizing ophthalmic delivery of a poorly water soluble drug from an aqueous in situ gelling system.Eur J Pharm Biopharm. 2020 Sep;154:1-7. doi: 10.1016/j.ejpb.2020.06.016. Epub 2020 Jun 27. Eur J Pharm Biopharm. 2020. PMID: 32599271
-
Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases.J Ocul Pharmacol Ther. 2020 Jul/Aug;36(6):323-341. doi: 10.1089/jop.2019.0109. Epub 2020 Apr 20. J Ocul Pharmacol Ther. 2020. PMID: 32310723 Review.
Cited by
-
Drug delivery methods based on nanotechnology for the treatment of eye diseases.Ann Med Surg (Lond). 2023 Oct 17;85(12):6029-6040. doi: 10.1097/MS9.0000000000001399. eCollection 2023 Dec. Ann Med Surg (Lond). 2023. PMID: 38098602 Free PMC article. Review.
-
Fluorescent Nanosystems for Drug Tracking and Theranostics: Recent Applications in the Ocular Field.Pharmaceutics. 2022 Apr 28;14(5):955. doi: 10.3390/pharmaceutics14050955. Pharmaceutics. 2022. PMID: 35631540 Free PMC article. Review.
-
Development and Evaluation of Cyclosporine a Mixed Micelle Eye Drops for Enhanced Ocular Drug Delivery.AAPS PharmSciTech. 2025 May 16;26(5):136. doi: 10.1208/s12249-025-03129-0. AAPS PharmSciTech. 2025. PMID: 40380025
-
Posaconazole micelles for ocular delivery: in vitro permeation, ocular irritation and antifungal activity studies.Drug Deliv Transl Res. 2022 Mar;12(3):662-675. doi: 10.1007/s13346-021-00974-x. Epub 2021 Apr 8. Drug Deliv Transl Res. 2022. PMID: 33830458
-
Peptidomimetics Therapeutics for Retinal Disease.Biomolecules. 2021 Feb 24;11(3):339. doi: 10.3390/biom11030339. Biomolecules. 2021. PMID: 33668179 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical